Aspire Biopharma Holdings (ASBP) Cash & Current Investments (2022 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Cash & Current Investments came in at $1.8 million in Q1 2026, up 35.66% year-on-year from $1.3 million in Q1 2025, and up 35.66% on a QoQ basis from $1.3 million in Q1 2025.
Aspire Biopharma Holdings (ASBP) Cash & Current Investments (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 5 years of Cash & Current Investments data on file, last reported at $1.8 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 35.66% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 35.66% increase from a year earlier, with the FY2024 full-year figure at $3633.0, down 67.49% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $1.8 million, up from $1.3 million in the prior quarter.
- Over the last five years, Cash & Current Investments for ASBP reached as high as $1.8 million in Q1 2026 and fell as low as $3633.0 in Q4 2024.
- Historically, Cash & Current Investments has averaged $484578.2 across 5 years, with a median of $406205.5 in 2022.
- Across the five-year window, Cash & Current Investments slumped 97.75% in 2023 and soared 2747.6% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $497259.0 in 2022, then slumped by 97.75% to $11174.0 in 2023, then tumbled by 67.49% to $3633.0 in 2024, then surged by 36964.22% to $1.3 million in 2025, then surged by 35.66% to $1.8 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $1.8 million in Q1 2026, $1.3 million in Q1 2025, and $3633.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | 60.03 Mn |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn | 4.79 Bn |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn | 7.25 Bn |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn | 8.75 Bn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn | 5.18 Bn |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn | 3.01 Bn |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -724,464.05 | 5,750.00 | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.83 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 3,633.00 |
| Sep 30, 2024 | 16,541.00 |
| Jun 30, 2024 | 19,604.00 |
| Mar 31, 2024 | 47,287.00 |
| Dec 31, 2023 | 11,174.00 |
| Mar 31, 2023 | 315,152.00 |
| Dec 31, 2022 | 497,259.00 |
| Sep 30, 2022 | 533,129.00 |
| Jun 30, 2022 | 579,751.00 |
| Mar 31, 2022 | 618,122.00 |